CLARiTI in the News

Researchers are making progress toward imaging markers that could detect TDP-43 pathology during life, but significant challenges remain before these tools are ready for widespread research and clinical use.

At the recent TDP-43 conference, researchers emphasized a unified push to develop reliable biomarkers for TDP-43 proteinopathies, which are implicated in conditions like ALS and frontotemporal dementia. Advancements highlighted include the progression of PET ligands into Phase 1 trials and the emergence of immunoassays targeting cryptic HDGFL2 peptides, signaling promising strides toward early detection and therapeutic monitoring.

Research participants have begun volunteering for brain scans at the University of Wisconsin School of Medicine and Public Health in Madison for a national study on Alzheimer’s disease and related dementias.

The University of Washington (UW) has received a portion of a new $150 million grant to collaborate on a study called Clarity in Alzheimer’s Disease and Related Dementias Research Through Imaging (CLARiTI). The five-year study funded by the National Institute on Aging will provide cutting-edge imaging and blood-based biomarker data for researchers worldwide to advance Alzheimer’s and related dementias research.

The University of Wisconsin School of Medicine and Public Health (SMPH) has been awarded funding from the National Institutes of Health (NIH) for a nationwide research initiative to investigate the neurobiology of Alzheimer’s disease and related dementias.